Also found in: Medical.
WOSCOPSWest of Scotland Coronary Prevention Study
References in periodicals archive ?
Packard said in presenting the 20-year WOSCOPS (West of Scotland Coronary Prevention Study) follow-up at the American Heart Association scientific sessions.
Undercutting that argument, however, was the WOSCOPS finding that the long-term benefits of 5 years of pravastatin were independent of age at treatment, Dr.
ABLE 1 PROFILE OF REDUCTION IN FATAL EVENTS FOR PATIENTS TREATED FOR HYPERCHOLESTEROLEMIA Trial Outcome Relative Risk Studied Reduction (%) 4S Group (2) Total mortality 29% Pts with history of CHD and elevated cholesterol CARE Trial (3) Fatal CHD 24% Pts with history of CHD but with average LDL levels LIPID Trial (4) Fatal CHD 24% Pts with history of CHD, broad range of cholesterol levels WOSCOPS Trial (5) Nonfatal MI 31% Pts with elevated or fatal coronary cholesterol, no CHD event Trial Absolute Risk Number Reduction Needed (percentage points) to Treat 4S Group (2) 6.
Data source: The study population included a combined sample of nondiabetic participants in five large-scale trials: ASCOT-LLA, JUPITER, WOSCOPS, MEGA, and AFCAPS/TexCAPS.
28) In the WOSCOPS trial, men with hypercholesterolemia (LDL-C [greater than or equal to] 155 mg/dL) and no history of myocardial infarction received pravastatin 40 mg or placebo.
TABLE 1 6 trials showed reduced cardiovascular morbidity and mortality after lowering LDL levels STUDY N TYPE POPULATION AFCAPS/ 6605 R, DB, PC Primary TexCAP (11) prevention WOSCOPS (12) 6595 R, DB, PC Primary prevention 4S (13) 4444 R, DB, PC Secondary prevention LIPID (14) 9014 R, DB, PC Secondary prevention HHS (15) 4081 R, DB, PC Primary prevention LRC-CPPT (16) 3806 R, DB, PC Primary prevention DURATION LDL STUDY INTERVENTION (YRS) REDUC.
Genetic studies of four randomized controlled clinical trials (CARE, WOSCOPS, PROVE IT, and PROSPER) found that statin treatment significantly reduced CHD events in carriers of the KIF6 variant.
2008) Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.
The first paper demonstrates that a gene variant in the KIF6 gene predicts increased risk for recurrent CHD events (the CARE study) and primary CHD events (the WOSCOPS study)1.
The risk of coronary events associated with the FCAR Asp92Asn polymorphism in both CARE and WOSCOPS was independent of other known risk factors.
Olukotun also played leading roles in the SAVE study involving captopril (Capoten(R)) and the WOSCOPS, LIPID and CARE studies of pravastatin (Pravachol(R)).